In-Vitro Evaluation of miR-101-5P Effect on Herpes Simplex Virus Replication

Document Type : Original Article (s)

Authors

1 Associate Professor, Department of Microbiology and Immunology, School of Medicine AND Autoimmune Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran

2 MSc Student, Department of Microbiology and Immunology, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran

3 MSc Student, Department of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

4 Associate Professor, Department of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

5 PhD Candidate, Department of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

6 Department of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Herpes simplex virus type 1 (HSV-1) is known worldwide for its serious disease and a kind of infection that involves nervous system throughout human lifelong. HSV-1 infection is much more considerable in immunocompromised patients and due to the growing resistance to its main drug, acyclovir, alternative treatments are required. MicroRNAs (miRNAs) regulate host and viral gene expression, post-transcriptionally. One previous study has shown that mir-101-3p expression may play role in HSV-1-infected cells.Methods: In this study, synthesized mimic hsa-miR-101-5p was transfected to HSV-1-infected Hela cells to observe its effect on HSV-1 replication via microscopic observation.Findings: Hela cells transfected by hsa-miR-101-5p produced less viral progeny, and expressed less cytopathic effects.Conclusion: Considering the effect of hsa-miR-101 in suppressing HSV-1 replication without affecting cell viability, this achievement can give us new insights in treatment of HSV-1 infection.

Keywords

References

  1. Boutell C, Sadis S, Everett RD. Herpes simplex virus type 1 immediate-early protein ICP0 and is isolated RING finger domain act as ubiquitin E3 ligases in vitro. J Virol 2002; 76(2): 841-50.
  2. Knipe DM, Cliffe A. Chromatin control of herpes simplex virus lytic and latent infection. Nat Rev Microbiol 2008; 6(3): 211-21.
  3. Bacon TH, Levin MJ, Leary JJ, Sarisky RT, Sutton D. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev 2003; 16(1): 114-28.
  4. Gaudreau A, Hill E, Balfour HH, Jr., Erice A, Boivin G. Phenotypic and genotypic characterization of acyclovir-resistant herpes simplex viruses from immunocompromised patients. J Infect Dis 1998; 178(2): 297-303.
  5. Darby G, Larder BA, Inglis AM. Evidence that the 'active centre' of the herpes simplex virus thymidine kinase involves an interaction between three distinct regions of the polypeptide. Gen Virol 1986; 67(4): 753-8.
  6. Danve-Szatanek C, Aymard M, Thouvenot D, Morfin F, Agius G, Bertin I, et al. Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up. J Clin Microbiol 2004; 42(1): 242-9.
  7. Wu J, Shen L, Chen J, Xu H, Mao L. The role of microRNAs in enteroviral infections. Braz J Infect Dis 2015; 19(5): 510-6.
  8. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010; 327(5962): 198-201.
  9. Wang X, Diao C, Yang X, Yang Z, Liu M, Li X, et al. ICP4-induced miR-101 attenuates HSV-1 replication. Sci Rep 2016; 6: 23205.
  10. Zeng Z, Zhang R, Hong W, Cheng Y, Wang H, Lang Y, et al. Histidine-rich Modification of a Scorpion-derived Peptide Improves Bioavailability and Inhibitory Activity against HSV-1. Theranostics 2018; 8(1): 199-211.
  11. Roehm PC, Shekarabi M, Wollebo HS, Bellizzi A, He L, Salkind J, et al. Inhibition of HSV-1 Replication by Gene Editing Strategy. Scientific Reports 2016; 6: 23146.
  12. van MJ, Kaspers GJ, Cloos J. Cell sensitivity assays: the MTT assay. Methods Mol Biol 2011; 731: 237-45.
  13. Xu L, Beckebaum S, Iacob S, Wu G, Kaiser GM, Radtke A, et al. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity. J Hepatol 2014; 60(3): 590-8.
  14. Santhakumar D, Forster T, Laqtom NN, Fragkoudis R, Dickinson P, Abreu-Goodger C, et al. Combined agonist-antagonist genome-wide functional screening identifies broadly active antiviral microRNAs. Proc Natl Acad Sci USA 2010; 107(31): 13830-5.
  15. Umbach JL, Kramer MF, Jurak I, Karnowski HW, Coen DM, Cullen BR. MicroRNAs expressed by herpes simplex virus 1 during latent infection regulate viral mRNAs. Nature 2008; 454(7205): 780-3.
  16. da Silva AS, Raposo JV, Pereira TC, Pinto MA, de Paula VS. Effects of RNA interference therapy against herpes simplex virus type 1 encephalitis. Antivir Ther 2016; 21(3): 225-35.
Journal of Isfahan Medical School
Volume 36, Issue 494 - Serial Number 494
July and August 2018
Pages 1024-1029

Files

History

  • Receive Date: 09 September 2018
  • Revise Date: 26 May 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics